Crossing the ADC inflection points: what separates clinical success from failure
Bioconjugate Insights · 23.02.2026 · 1 (1) · 41–48
DOI: 10.18609/bci.2026.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 23.02.2026. Verfasst von Antoine Yver. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“Drug development is not a race to be first; it is a race to win. History is full of examples where being first did not matter, but being right did.” Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Antoine Yver, Board Chair, Ona Therapeutics, with more than three and a half decades of experience shaping global cancer drug development. In this conversation, they explore what determines whether an ADC successfully crosses the critical threshold and how teams should rethink dose finding, toxicity, and what it truly takes to set a program up for long-term success in the clinic.
Zitieren
APA
Yver, A. (2026). Crossing the ADC inflection points: what separates clinical success from failure. Bioconjugate Insights, 1(1), 41–48. https://doi.org/10.18609/bci.2026.007
Vancouver
Yver A. Crossing the ADC inflection points: what separates clinical success from failure. Bioconjugate Insights. 2026;1(1):41–48. doi:10.18609/bci.2026.007
BibTeX
@article{Yver2026,
author = {Yver, Antoine},
title = {Crossing the ADC inflection points: what separates clinical success from failure},
journal = {Bioconjugate Insights},
year = {2026},
volume = {1},
number = {1},
pages = {41–48},
doi = {10.18609/bci.2026.007}
}
EUVIMED